Supplementary Tables S1-S15 from Tracing Founder Mutations in Circulating and Tissue-Resident Follicular Lymphoma Precursors

Supplementary Table S1. Patient and control clinical characteristics Supplementary Table S2. Sequencing metrics for FL cases & controls Supplementary Table S3. Identified mutations in EPIC FL pre-diagnostic samples Supplementary Table S4. Identified mutations in control samples Supplementary Table S5. Statistical significance for detection in prediagnostic samples with paired tumor biopsy Supplementary Table S6. Identified mutations in FL tumors with detection in paired prediagnostic samples Supplementary Table S7. Paired tumor cohort histology & sample characteristics Supplementary Table S8. Identified mutations in paired biopsy samples Supplementary Table S9. Clonal VDJ rearrangements in paired biopsies Supplementary Table S10. Concordance analysis of paired biopsy samples Supplementary Table S11. Patient characteristics, marrow and sorting studies Supplementary Table S12. DNA and sequencing metrics for marrow and sorting studies Supplementary Table S13. Monoclonal antibodies and manufacturers Supplementary Table S14. Mutations detected in marrow and sorting studies Supplementary Table S15. Genes fully or partially covered in lymphoma-focused CAPP-Seq selector

补充表S1. 患者与对照人群临床特征
补充表S2. 滤泡性淋巴瘤（Follicular Lymphoma, FL）病例与对照样本的测序指标
补充表S3. EPIC队列滤泡性淋巴瘤（FL）诊断前样本中鉴定的突变
补充表S4. 对照样本中鉴定的突变
补充表S5. 配对肿瘤活检样本匹配的诊断前样本检测的统计学显著性
补充表S6. 滤泡性淋巴瘤（FL）肿瘤样本中鉴定的、可在配对诊断前样本中检测到的突变
补充表S7. 配对肿瘤队列的组织学与样本特征
补充表S8. 配对活检样本中鉴定的突变
补充表S9. 配对活检样本中的克隆性VDJ重排
补充表S10. 配对活检样本的一致性分析
补充表S11. 患者特征、骨髓与分选实验相关资料
补充表S12. 骨髓与分选实验的DNA及测序指标
补充表S13. 单克隆抗体及其生产厂商
补充表S14. 骨髓与分选实验中检测到的突变
补充表S15. 淋巴瘤靶向CAPP-Seq捕获探针组（CAPP-Seq）完全或部分覆盖的基因